Knowledge gained through genetic sequencing of tumors has led cancer centers to change treatment methods and sparked competition among drugmakers to develop targeted therapies. "What we're seeing is the beginning of a revolution in therapeutics," said Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Related Summaries